Search

everythinglearnresearchcommunity

for

Search:↓

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Topical JAK inhibitors may help children with alopecia areata regrow hair.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

Tofacitinib may effectively treat folliculitis decalvans.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.